• November 21, 2023  

    High-Energy Blue Light Powers a Promising New Treatment to Destroy Cancer Cells

    With: Stuart L. Marcus, MD, PhD

    A perennial challenge in cancer treatment is figuring out how to kill tumor cells while leaving healthy cells unharmed. Our Curious Dr. George asks Stuart L. Marcus, MD, PhD, founder and Chief Science Officer at SonALAsense, how his company’s light-activated drug treatment addresses this challenge, holding potential promise for people with brain, bladder, and possibly other cancers. Curious Dr. George: Your flagship treatment employs… Read more »

  • October 24, 2023  

    How Would an Expert Manage His Own Acute Myelogenous Leukemia?

    With: Adam Asch, MD

    When facing a frightening new cancer diagnosis, some people ask their doctors, “What would you do if you were me?” Here, our Curious Dr. George asks leukemia expert Adam Asch, MD, how he would handle his own case of acute myelogenous leukemia. Dr. Asch is Professor of Medicine and Nancy Johnson Records Chair of Oncology at the University of Oklahoma College of Medicine. Curious… Read more »

  • September 5, 2023  

    How Would an Expert Manage His Own Advanced Esophageal Cancer?

    With: Sarbajit Mukherjee, MD, MS

    When facing a frightening new cancer diagnosis, some people ask their doctors, “What would you do if you were me?” Here, our Curious Dr. George asks gastrointestinal cancer expert Sarbajit Mukherjee, MD, MS, how he would handle his own case of advanced esophageal cancer. Dr. Mukherjee is Assistant Professor in the Department of Medicine—GI Medical Oncology and Co-Leader of the GI Translational Research Group… Read more »

  • August 18, 2023  

    Alibrex: A New Blood Test to Reveal Whether a Cancer Treatment is Working

    With: Kevin Knopf, MD, MPH

    In cancer treatment, time is of the essence. Our Curious Dr. George asks Kevin B. Knopf, MD, MPH, Chief Medical Officer at Cadex Genomics, how his company’s new test, Alibrex, could rapidly reveal how well a given treatment is working for a given patient. Curious Dr. George: The U.S. Food and Drug Administration has approved about 270 anti-cancer drugs. The National Comprehensive Cancer Network… Read more »

  • August 11, 2023  

    Common Sense Oncology: Moving Back Towards Outcomes that Matter

    With: Christopher M. Booth, MD, FRCPC

    There are many ways to measure how well a particular cancer treatment works. But how much do these outcomes reflect a patient’s actual wellbeing? Our Curious Dr. George asks Christopher M. Booth, MD, FRCPC, one of the founding leaders of the new international initiative “Common Sense Oncology” (CSO), how CSO is working to improve patient outcomes. Curious Dr. George: The practice of clinical oncology… Read more »

  • June 30, 2023  

    PARIS Test Uses Lab-Grown Mini-Tumors to Find a Patient’s Best Treatment

    With: Carla Grandori, MD, PhD

    The U.S. Food and Drug Administration (FDA) has approved hundreds of drugs for the treatment of cancer. However, some approved drugs are more effective for certain patients than others. Our curious Dr. George asks Carla Grandori, MD, PhD, Founder and CEO of SEngine Precision Medicine, about her company’s test to detect which drugs are likely to be most effective for a given patient’s solid tumor.… Read more »

  • May 20, 2023  

    How Would an Expert Manage His Own Advanced Bladder Cancer?

    With: Daniel E.C. Fein, MD

    When facing a frightening new cancer diagnosis, some people ask their doctors, “What would you do if you were me?” Here, our Curious Dr. George asks Daniel E.C. Fein, MD, how he would handle his own case of advanced bladder cancer. Dr. Fein is a genitourinary oncologist at Beth Israel Deaconess Medical Center (BIDMC) in Boston, MA, as well as an Instructor in Medicine… Read more »

  • March 7, 2023  

    Learnings from Pilot Study: Creating Treatment Templates to Serve More Glioblastoma Patients

    With: Adrienne Nugent, PhD

    A recent pilot study between Cancer Commons and the Musella Foundation for Brain Tumor Research & Information is identifying patterns that are being translated into treatment templates to better serve a larger group of GBM patients. Our Curious Dr. George asks Cancer Commons Scientist Adrienne Nugent, PhD, to discuss key factors that point to the best courses of action a patient might take, and about the clinical… Read more »

  • January 17, 2023  

    How Would an Expert Manage His Own Advanced Hodgkin Lymphoma?

    With: Kevin Knopf, MD, MPH

    When facing a frightening new cancer diagnosis, some people ask their doctors, “What would you do if you were me?” Here, our Curious Dr. George asks oncologist Kevin Knopf, MD, how he would handle his own advanced Hodgkin lymphoma. Curious Dr. George: Please consider this hypothetical scenario: as a very busy practicing clinical oncologist during the COVID-19 pandemic, you were not paying much attention… Read more »

  • September 6, 2022  

    Molecular Alterations Associated With Improved Outcome in Patients With Glioblastoma Treated With Tumor-Treating Fields Bookmark

    George Lundberg, MD

    Do molecular biomarkers have any role in treating glioblastoma (GBM)? As outlined in this scientific research report from the academic journal Neuro-Oncology Research Advances, a recent study found that 3 biomarkers were correlated with very great outcome differences for people treated with tumor-treating (electrical) fields.

    .

    .